Bain Capital Life Sciences Entities Reduce Stake in NewAmsterdam Pharma Below 5% Threshold

On May 14, 2026, BCLS II Investco, LP and associated Bain Capital Life Sciences entities filed Amendment No. 6 to their Schedule 13D for NewAmsterdam Pharma Company N.V. (NAMS). The filing details a series of significant divestments occurring between May 8 and May 12, 2026. Specifically, BCLS II Investco sold a total of 183,540 ordinary shares across three trading days at weighted average prices ranging from $37.22 to $39.98 per share. Following the final sale on May 12, which involved the disposal of 152,076 shares by BCLS II Investco and over 2.7 million shares by BCLS Fund III, the reporting group collectively ceased to beneficially own 5% or more of the Issuer's outstanding ordinary shares. As of the filing date, BCLS II Investco directly holds 114,017 shares, representing approximately 0.1% of the class. The aggregate beneficial ownership of the reporting group now stands at approximately 3.3%, which includes ordinary shares and various warrants.